.Nature Medicine, Posted online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec acquired FDA authorization after an adverse trial, which highlights the numerous difficulties and also difficulties of medicine advancement within this setting.